Image source: © 2025 Krish Capital Pty. Ltd.

Highlights

  • PYC’s H1FY25 revenue rose by 39.13% YoY, while cash and cash equivalents surged by 93.81% YoY.
  • The company’s VP-001 for RP11 advanced to registrational trials with FDA acceptance, targeting NDA submission in H2FY25.
  • PYC’s PMS candidate is expected to enter clinical trials within 12 months for an untreatable neurodevelopmental disorder.

PYC Therapeutics Limited (ASX:PYC) is a clinical-stage biotechnology company which develops precision RNA therapies for untreatable monogenic diseases using its proprietary delivery platform to enhance RNA drug potency.

In the first half of the financial year 2025 (H1FY25), the company witnessed 39.13% YoY increase in revenue to AUD 12.69 million, driven by research collaboration, R&D tax incentive, and interest income. Cash and cash equivalents surged by 93.81% YoY to AUD 49.25 million in H1FY25, up from AUD 25.41 million in H1FY24. The loss after income tax stood at AUD 25.87 million, compared to a loss of AUD 15.26 million in H1FY24, due to increased R&D expenses related to advancing drug candidates and conducting clinical trials.

Business Update

Through an ASX update, PYC informed that it has advanced its VP-001 program for Retinitis Pigmentosa type 11, with the FDA accepting its registrational trial design following positive Phase 1/2 results which includes sham control and key endpoints, requiring 24-month data for NDA submission in H2FY25.

Through another update, the company announced that its PYC-002 candidate for Phelan-McDermid Syndrome showed preclinical success in restoring SHANK3 gene expression and improving brain function, with human clinical trials expected to begin in 2026.

Company Outlook

PYC anticipates its PMS drug candidate to enter clinical trials within 12 months, offering first-in-class potential for a currently untreatable neurodevelopmental disorder. Meanwhile, VP-001 for RP11 is advancing toward a registrational Phase 2/3 trial, with the FDA-guided initiation expected in the H2FY25.

PYC’s ADOA drug candidate continues dose escalation studies, with human safety and efficacy data expected in 2025, targeting a significant unmet need in blinding eye disease. With AUD 175.2 million in funding secured, the company is capitalised through 2027 and positioned for multiple human efficacy readouts.

Stock Information

In a month, PYC stock price has increased by approximately 8.33% and has recorded a drop of about 0.98% over the last six months. The stock has a 52-week high of AUD 2.08, recorded on 22 October 2024 and 52-week low of AUD 0.89, recorded on 31 July 2024. As of 2 July 2025, PYC closed at AUD 1.3 per share.

Support and Resistance Summary

Note 1: Past performance is not a reliable indicator of future performance.

Note 2: The reference data for all price data, currency, technical indicators, support, and resistance levels is 2 July 2025. The reference data in this report has been partly sourced from EODHD/Others.

 

Technical Indicators Defined

Support: A level at which the stock prices tend to find support if they are falling, and a downtrend may take a pause backed by demand or buying interest. Support 1 refers to the nearby support level for the stock and if the price breaches the level, then Support 2 may act as the crucial support level for the stock.

Resistance: A level at which the stock prices tend to find resistance when they are rising, and an uptrend may take a pause due to profit booking or selling interest. Resistance 1 refers to the nearby resistance level for the stock and if the price surpasses the level, then Resistance 2 may act as the crucial resistance level for the stock.